Chordia Therapeutics Inc. (JP:190A) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chordia Therapeutics Inc. presented results from a Phase 1 clinical trial of their drug CTX-712 at the Japanese Society of Hematology meeting, highlighting its potential as a selective inhibitor of CLK, which is important in cell proliferation and cancer treatment. The study, involving 14 patients with hematologic malignancies, supports the ongoing research and development of novel cancer therapies by the biotech company. CTX-712 is also undergoing a Phase 1/2 clinical trial in the U.S., with Chordia focused on developing further preclinical assets, including a CDK12 inhibitor and GCN2 inhibitors.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.